Pharmaceutical exporter to Thailand

Yes. The Thai FDA accepts WHO-GMP certification from Indian manufacturing sites for ACTD dossier submissions, provided the certificate is current, issued by a recognised competent authority such as the Central Drugs Standard Control Organization or a state-level FDA, and accompanied by the manufacturing licence and recent inspection observations. Many of our source plants additionally hold EU-GMP certification, which carries weight with TFDA reviewers on oncology, biologic, and complex injectable submissions. We file the certificates in Module 1 of the ACTD with Thai-translated administrative cover, and we maintain a renewal tracker so the underlying GMP cover never lapses on a registered SKU.

The Government Pharmaceutical Organization plays three roles simultaneously. It manufactures domestic generics, it distributes pharmaceuticals to Thai state hospitals, and it imports through procurement tenders for therapy areas it does not produce. For an Indian supplier, the realistic GPO opportunity sits in that import-tender role, particularly for oncology, biologics, second-line anti-infectives, and specialised injectables. We respond to GPO tender notices with full technical and commercial dossiers, supported by our TFDA-licensed importer partner who acts as the local registration holder and clearing entity. Pricing pressure is real, so our submissions come from EU-GMP plants with credible quality history.

From Mumbai Nhava Sheva to Laem Chabang we plan for fifteen to nineteen days of port-to-port transit on direct or single-transhipment services. Singapore is the most common transhipment hub. We add three to five working days for Thai customs clearance buffer, with our broker pre-filing import documentation while the vessel is still at sea so the customs clock starts before the container lands. Laem Chabang is a well-run deep-water port with minimal congestion under normal conditions. Cold-chain biologics ship by air rather than sea, with 24 to 36 hour transit on Thai Airways or transhipped via Singapore or Hong Kong.

Yes. Our Bangkok regulatory consultants handle Thai-language translation of administrative dossier sections, labelling, patient information leaflets, and Thai-text overlays on carton and inner-label artwork. Translation is notarised where TFDA requests it, and final regulatory artwork is signed off before printing plates are released to the manufacturing site. The full technical CTD modules are filed in English, but the Thai-facing materials are localised. We do not push Thai translation onto the importer because translation rework is one of the most common TFDA delay causes and we would rather absorb that step in-house.

Yes, that is precisely the point of the ASEAN Common Technical Dossier format. Vietnam, Malaysia, the Philippines, and Indonesia accept the same fundamental dossier structure, with country-specific adaptations for Module 1 administrative content, language translation, labelling artwork, and certain stability declarations. Our regulatory team builds master ACTD files at the molecule level and runs country-specific adaptations rather than rewriting from scratch, which compresses ASEAN-wide registration timelines for buyers operating across multiple markets. Thailand's TFDA review tends to be the more demanding among ASEAN regulators, so a Thai-passed dossier gives confidence for adjacent filings.

Thai local manufacturing, both private and through GPO, runs efficient lines on commodity oral solid generics and some basic injectables, and import pricing struggles to compete on those categories. Our positioning is therefore selective. We focus on EU-GMP oncology, biologics, second-line anti-infectives, and specialised injectables where Thai local capacity is constrained or where regulatory positioning genuinely matters to the procurement decision. On those categories, Indian EU-GMP supply is competitive against European originator pricing, which is the comparison Thai oncology and biologic procurement actually runs. We do not pretend to compete head-on with GPO on commodity production.

Yes. The ASEAN-India Free Trade Area agreement and the India-Thailand Free Trade Agreement framework reduce or eliminate customs duty on most pharmaceutical tariff codes from Indian origin into Thailand, subject to rules of origin compliance. Our shipments include a Form AI Certificate of Origin issued by the Indian competent authority, which the Thai importer presents at customs to claim the preferential rate. Eligibility depends on the specific HS code and the value-added rules, and our documentation team confirms qualification before each shipment rather than assuming the preference applies. The duty saving is meaningful on tender pricing math.